PMID- 23374617
OWN - NLM
STAT- MEDLINE
DCOM- 20130717
LR  - 20211203
IS  - 1942-5546 (Electronic)
IS  - 0025-6196 (Linking)
VI  - 88
IP  - 2
DP  - 2013 Feb
TI  - Twelve-month frequency of drug-metabolizing enzyme and transporter-based 
      drug-drug interaction potential in patients receiving oral enzyme-targeted kinase 
      inhibitor antineoplastic agents.
PG  - 139-48
LID - S0025-6196(12)01089-0 [pii]
LID - 10.1016/j.mayocp.2012.10.020 [doi]
AB  - OBJECTIVE: To describe 12-month rates and patterns of coprescription of drugs 
      that potentially create drug-drug interactions (DDIs) through shared metabolic or 
      transport pathways for 9 enzyme-targeted kinase inhibitor oral antineoplastic 
      drugs (OADs). PATIENTS AND METHODS: We used a deidentified pharmacy claims 
      database identifying patients prescribed dasatinib, erlotinib, everolimus, 
      imatinib, lapatinib, nilotinib, pazopanib, sorafenib, or sunitinib between 
      January 1, 2008, and May 31, 2010. Coprescribing was 1 or more overlapping days 
      of supply between the OAD and potential DDI drugs during the 12-month period 
      beginning on the OAD index date. Product labels identified the cytochrome P450 
      metabolic enzymes used and whether P-glycoprotein was used by the OADs. Drugs 
      that induce and/or inhibit these pathways were identified from the label and 
      online resources. RESULTS: Sample sizes ranged from 96 (pazopanib group) to 4617 
      (imatinib group). Coprescribing rates with drugs that may decrease OAD 
      effectiveness were 359/1546 (23%) (sunitinib group) to 1851/3263 (57%) (erlotinib 
      group). Coprescribing rates with drugs that may increase OAD toxicity were 
      364/1546 (24%) (sunitinib group) to 71/96 (74%) (pazopanib group). Patients 
      coprescribed DDI drugs had a median of 1 to 4 more medications present on the OAD 
      index date than those not coprescribed a DDI drug. Most groups coprescribed DDI 
      drugs had a median of 180 or more OAD days of supply during follow-up. The 
      proportion of OAD days of supply with overlapping days of DDI drugs ranged from 
      7% to 85%. Generally, oncologists prescribed the OAD and nononcologists the DDI 
      drug. CONCLUSION: Coprescription of drugs that induce or inhibit metabolic 
      pathways used by enzyme-targeted kinase inhibitor OADs is high. The clinical 
      consequences need further study.
CI  - Copyright (c) 2013 Mayo Foundation for Medical Education and Research. Published by 
      Elsevier Inc. All rights reserved.
FAU - Bowlin, Steven J
AU  - Bowlin SJ
AD  - Medco Research Institute LLC, Medco Health Solutions Inc, an Express Scripts 
      Company, Bethesda, MD, USA. sjbowlin1@gmail.com
FAU - Xia, Fang
AU  - Xia F
FAU - Wang, Wenyi
AU  - Wang W
FAU - Robinson, Keisha D
AU  - Robinson KD
FAU - Stanek, Eric J
AU  - Stanek EJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings
JID - 0405543
RN  - 0 (Benzamides)
RN  - 0 (Indazoles)
RN  - 0 (Piperazines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 7RN5DR86CK (pazopanib)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
SB  - IM
CIN - Mayo Clin Proc. 2013 Feb;88(2):126-8. PMID: 23374616
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/*therapeutic use
MH  - Benzamides/administration & dosage/adverse effects
MH  - Child
MH  - Cohort Studies
MH  - Databases, Pharmaceutical
MH  - Drug Interactions
MH  - Female
MH  - Humans
MH  - Imatinib Mesylate
MH  - Indazoles
MH  - Male
MH  - Middle Aged
MH  - Piperazines/administration & dosage/adverse effects
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Protein Kinase Inhibitors/*administration & dosage
MH  - Pyrimidines/administration & dosage/adverse effects
MH  - Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors
MH  - Retrospective Studies
MH  - Sulfonamides/administration & dosage
MH  - United States
MH  - Young Adult
EDAT- 2013/02/05 06:00
MHDA- 2013/07/19 06:00
CRDT- 2013/02/05 06:00
PHST- 2012/07/09 00:00 [received]
PHST- 2012/10/10 00:00 [revised]
PHST- 2012/10/31 00:00 [accepted]
PHST- 2013/02/05 06:00 [entrez]
PHST- 2013/02/05 06:00 [pubmed]
PHST- 2013/07/19 06:00 [medline]
AID - S0025-6196(12)01089-0 [pii]
AID - 10.1016/j.mayocp.2012.10.020 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 2013 Feb;88(2):139-48. doi: 10.1016/j.mayocp.2012.10.020.